Literature DB >> 20823287

Amikacin monotherapy for sepsis caused by panresistant Pseudomonas aeruginosa.

Brice Layeux1, Fabio Silvio Taccone, David Fagnoul, Jean-Louis Vincent, Frédérique Jacobs.   

Abstract

Two patients with severe sepsis due to panresistant Pseudomonas aeruginosa, deteriorating despite therapy with colistin and β-lactams, were cured with a high daily dose (25 to 50 mg/kg) of amikacin to obtain a peak/MIC ratio of at least 8 to 10 (MIC = 16 μg/ml). Concomitant use of continuous venovenous hemodiafiltration (CVVHDF) provided no deterioration in renal function after treatment. High dosage of aminoglycosides combined with CVVHDF may represent a valuable therapeutic option for infection due to multiresistant pathogens.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20823287      PMCID： PMC2976156          DOI： 10.1128/AAC.00441-10

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  13 in total

Review 1.  Antibiotic dosing in critically ill adult patients receiving continuous renal replacement therapy.

Authors:  Robin L Trotman; John C Williamson; D Matthew Shoemaker; William L Salzer
Journal:  Clin Infect Dis       Date:  2005-09-12       Impact factor: 9.079

Review 2.  Nosocomial infections due to multidrug-resistant Pseudomonas aeruginosa: epidemiology and treatment options.

Authors:  Marilee D Obritsch; Douglas N Fish; Robert MacLaren; Rose Jung
Journal:  Pharmacotherapy       Date:  2005-10       Impact factor: 4.705

3.  Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity.

Authors:  M J Rybak; B J Abate; S L Kang; M J Ruffing; S A Lerner; G L Drusano
Journal:  Antimicrob Agents Chemother       Date:  1999-07       Impact factor: 5.191

Review 4.  Back to the future: using aminoglycosides again and how to dose them optimally.

Authors:  George L Drusano; Paul G Ambrose; Sujata M Bhavnani; Joseph S Bertino; Ann N Nafziger; Arnold Louie
Journal:  Clin Infect Dis       Date:  2007-08-08       Impact factor: 9.079

5.  Suboptimal aminoglycoside dosing in critically ill patients.

Authors:  Rhonda S Rea; Blair Capitano; Robert Bies; Kristin L Bigos; Randall Smith; Howard Lee
Journal:  Ther Drug Monit       Date:  2008-12       Impact factor: 3.681

6.  Revisiting the loading dose of amikacin for patients with severe sepsis and septic shock.

Authors:  Fabio Silvio Taccone; Pierre-François Laterre; Herbert Spapen; Thierry Dugernier; Isabelle Delattre; Brice Layeux; Daniel De Backer; Xavier Wittebole; Pierre Wallemacq; Jean-Louis Vincent; Frédérique Jacobs
Journal:  Crit Care       Date:  2010-04-06       Impact factor: 9.097

7.  Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration.

Authors:  R D Moore; P S Lietman; C R Smith
Journal:  J Infect Dis       Date:  1987-01       Impact factor: 5.226

8.  Does combination antimicrobial therapy reduce mortality in Gram-negative bacteraemia? A meta-analysis.

Authors:  Nasia Safdar; Jo Handelsman; Dennis G Maki
Journal:  Lancet Infect Dis       Date:  2004-08       Impact factor: 25.071

Review 9.  Clinical pharmacokinetics during continuous haemofiltration.

Authors:  F Bressolle; J M Kinowski; J E de la Coussaye; N Wynn; J J Eledjam; M Galtier
Journal:  Clin Pharmacokinet       Date:  1994-06       Impact factor: 6.447

Review 10.  Review of studies of the impact on Gram-negative bacterial resistance on outcomes in the intensive care unit.

Authors:  Andrew F Shorr
Journal:  Crit Care Med       Date:  2009-04       Impact factor: 7.598
View more
  20 in total

Review 1.  Management of antimicrobial use in the intensive care unit.

Authors:  Francisco Álvarez-Lerma; Santiago Grau
Journal:  Drugs       Date:  2012-03-05       Impact factor: 9.546

Review 2.  Therapies for multidrug resistant and extensively drug-resistant non-fermenting gram-negative bacteria causing nosocomial infections: a perilous journey toward 'molecularly targeted' therapy.

Authors:  Nadim G El Chakhtoura; Elie Saade; Alina Iovleva; Mohamad Yasmin; Brigid Wilson; Federico Perez; Robert A Bonomo
Journal:  Expert Rev Anti Infect Ther       Date:  2018-01-16       Impact factor: 5.091

3.  Proposal of a pharmacokinetically optimized dosage regimen of antibiotics in patients receiving continuous hemodiafiltration.

Authors:  Takehito Yamamoto; Nobuhiro Yasuno; Shoichi Katada; Akihiro Hisaka; Norio Hanafusa; Eisei Noiri; Naoki Yahagi; Toshiro Fujita; Hiroshi Suzuki
Journal:  Antimicrob Agents Chemother       Date:  2011-09-12       Impact factor: 5.191

4.  Appropriate antibiotic dosage levels in the treatment of severe sepsis and septic shock.

Authors:  Fabio Silvio Taccone; Maya Hites; Marjorie Beumier; Sabino Scolletta; Frédérique Jacobs
Journal:  Curr Infect Dis Rep       Date:  2011-10       Impact factor: 3.725

5.  Pharmacodynamic Evaluation of Plasma and Epithelial Lining Fluid Exposures of Amikacin against Pseudomonas aeruginosa in a Dynamic In Vitro Hollow-Fiber Infection Model.

Authors:  Aaron J Heffernan; Fekade B Sime; Derek S Sarovich; Michael Neely; Yarmarly Guerra-Valero; Saiyuri Naicker; Kyra Cottrell; Patrick Harris; Katherine T Andrews; David Ellwood; Steven C Wallis; Jeffrey Lipman; Keith Grimwood; Jason A Roberts
Journal:  Antimicrob Agents Chemother       Date:  2020-08-20       Impact factor: 5.191

Review 6.  Individualising Therapy to Minimize Bacterial Multidrug Resistance.

Authors:  A J Heffernan; F B Sime; J Lipman; J A Roberts
Journal:  Drugs       Date:  2018-04       Impact factor: 9.546

7.  Once-daily amikacin dosing in burn patients treated with continuous venovenous hemofiltration.

Authors:  Kevin S Akers; Jason M Cota; Christopher R Frei; Kevin K Chung; Katrin Mende; Clinton K Murray
Journal:  Antimicrob Agents Chemother       Date:  2011-08-08       Impact factor: 5.191

Review 8.  Pharmacological considerations for the proper clinical use of aminoglycosides.

Authors:  Spyridon Pagkalis; Elpis Mantadakis; Michael N Mavros; Christina Ammari; Matthew E Falagas
Journal:  Drugs       Date:  2011-12-03       Impact factor: 9.546

9.  Influence of multidrug resistance and appropriate empirical therapy on the 30-day mortality rate of Pseudomonas aeruginosa bacteremia.

Authors:  Laura Morata; Nazaret Cobos-Trigueros; José A Martínez; Alex Soriano; Manel Almela; Francesc Marco; Holguer Sterzik; Raquel Núñez; Cristina Hernández; José Mensa
Journal:  Antimicrob Agents Chemother       Date:  2012-07-02       Impact factor: 5.191

10.  SIMULTANEOUS IN VITRO SIMULATION OF MULTIPLE ANTIMICROBIAL AGENTS WITH DIFFERENT ELIMINATION HALF-LIVES IN A PRE-CLINICAL INFECTION MODEL.

Authors:  Iordanis Kesisoglou; Brianna M Eales; Kimberly R Ledesma; Paul R Merlau; Vincent H Tam; Weiqun Wang; Michael Nikolaou
Journal:  Comput Chem Eng       Date:  2021-09-13       Impact factor: 3.845
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.